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Prevention of ventilator-associated pneumonia (VAP) remains a
main objective in infection control in intensive care units (ICUs) [1,2]
as VAP is associated with signiﬁcant morbidity and possibly mortality
in critically ill patients [3-5]. Maintaining or improving oral hygiene by
means of an oral care protocol is an essential part of the comprehensive
approach needed to reduce VAP risk and in this regard the use of mouth
rinses with an antiseptic agent is considered pivotal. Since years chlor-
hexidine gluconate (CHG) has been themost frequently used antiseptic
agent for oral care in ICU patients [6] and ameta-analysis demonstrated
its value in terms of VAP prevention [7]. From this meta-analysis it ap-
peared that higher concentrations of CHG (2%) were more effective
than the more frequently used 0.12 or 0.2% solutions, but until now
head-to-head comparisons were lacking.
Therefore we read with interest the research article by Zand et al.
concerning the effects of oral rinse 0.2% and 2% CHG on rates of VAP in
adult ICU patients [8]. Based on a randomized trial the authors conclud-
ed that a higher CHG concentration (2%) resulted in reduced rates of
oropharyngeal colonization and VAP while no difference was observed
in oropharyngeal adverse events, length of mechanical ventilation,
ventilator-free days at day 28, and mortality. We question however
whether the sample size of patients exposed to 0.2% and 2% CHG
(n = 57 in both) was solid enough to demonstrate any difference in
the secondary outcomes. Based on a preliminary analysis of a multicen-
ter decolonization trial in ICUs, Platinga et al. reported a substantial pro-
portion of patients suffering from oral lesions [9]. In this cohort, 29 out
of 295 patients experienced mucosal lesions such as bleeding, plaque
formation, erosive abrasions and ulcerations. A relationship with in-
creased exposure to 2% CHG was assumed as oral lesions were more
common among patients residing in the ICU and with more prolonged
mechanical ventilation. In all patients lesions disappeared after discon-
tinuation of the 2% CHG oral rinsing. The study safety committee decid-
ed to replace the 2% CHG solution by a 1% CHG gel after which adverse
events rates dropped (2/419 patients).
In the same line we believe the trial by Zand et al. had insufﬁcient
study power to detect differences in mortality. Given theworrisome re-
ports by Klompas et al. we believemortality cannot be considered a sec-
ondary outcome variable in studies on oral care with CHG [10,11]. In a
meta-analysis pooling randomized placebo-controlled trials on CHG
oral care, Klompas et al. found a trend towards higher mortality in pa-
tients with CHG mouth rinses (relative risk (RR) 1.13; 95% conﬁdence
interval (CI), 0.99–1.29), despite a signiﬁcantly reduced risk for pneu-
monia in cardiac surgery patients (RR, 0.56, 95% CI, 0.41–0.77) and a
non-signiﬁcant reduced risk in non-cardiac surgery patients (RR, 0.88;
95% CI, 0.66–1.16) [10]. Interestingly, in a sensitivity-analysis the au-
thors found a trend towards increased mortality risk with the use of
higher CHG concentrations. In addition, in a more recent retrospective
cohort including 5539 patients mechanically ventilated for at leasthttp://dx.doi.org/10.1016/j.jcrc.2017.04.032
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to be signiﬁcantly associated with ventilator mortality (hazard ratio
1.63; 95% CI, 1.15–2.31) [11]. This observation only fed the controversy
on the usefulness of CHG rinses. In any case, it is clear that the potential
deleterious effect of CHG oral rinse in terms of mortality (if any) can
only be detected in large numbers of patients. As such, we plea for stud-
ies designed with sufﬁcient statistical power to detect the eventual
harmful effects of CHG on survival.
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